Bimekizumab

Status:
Red
Decision Date:
October 2021
 

Comments

RED:

  • NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis.
  • NICE TA916: Bimekizumab for treating active psoriatic arthritis. ICB commissioned (decision date November 2023)
  • NICE TA918: Bimekizumab for treating axial spondyloarthritis. ICB commissioned (decision date November 2023)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app